Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system

Hypertension

Volumn 32, Issue 3, 1998, Pages 387-392

  Hollenberg, Norman K ^a   Fisher, Naomi D L ^a   Price, Deborah A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN II ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALKIREN; EPROSARTAN; IRBESARTAN; KININ; LISINOPRIL; PLACEBO; RAMIPRIL; RENIN; RENIN INHIBITOR; SERINE PROTEINASE; ZANKIREN;

CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN EXPERIMENT; KIDNEY PERFUSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

EID: 0031688757     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.3.387     Document Type: Conference Paper

References (36)

1. Tigerstedt R, Bergman PG. Niere and Krieslauf. Skandinav Arch Physiol. 1898;8:223.
2. Haber E. The role of renin in normal and pathological cardiovascular homeostasis. Circulation. 1976;54:849-861.
3. Cushman DW, Cheung HS, Saho EF, Ondetti MA. Angiotensin converting enzyme inhibitors: evolution of a new class of antihypertensive drugs. In: Horovitz ZP, ed. Angiotensin Converting Enzyme Inhibitors: Mechanisms of Action and Clinical Implications. Baltimore, Md: Urban & Schwarzenberg; 1981:3-25.
4. Barajas L, Bing J, Boucher R, Deodhar S, Genest J, Goldblatt H, Gross F, Smeby RR, Haas E, Hartroft PM, Helmer O, Latta H, Lentz K, Peart WS, Skeggs LT, Bumpus FM. Renin. In: Page IH, McCubbin JW, eds. Renal Hypertension. Chicago, Ill: Year Book Medical Publishers Inc; 1969:14-61.
5. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol. 1993;62:207-210.
6. Cornish KG, Joyner WL, Gilmore JP. Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res. 1979;44:540-544.
7. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984;2: 277-284.
8. Okunishi H, Miyazaki M, Okamura H, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun. 1987;149:1186-1192.
9. Okamura T, Okunishi H, Ayajiki K, Toda N. Conversion of angiotensin I to angiotensin II in rabbit aorta. Hypertension. 1984;6:216-221.
10. Wintroub BU, Schechter NB, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Dermatol. 1984;83:336-339.
11. Saye JA, Singer HA, Peach MJ. Role of endothelium in conversion of angiotensin I to angiotensin II in rabbit aorta. Hypertension. 1984;6: 216-221.
12. Oliver JA, Sciacca RR. Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest. 1984; 74:1247-1251.
13. Campbell DJ, Ziogas J, Kladis A. Metabolism of tetradecapeptide, angiotensinogen and angiotensin I and II by isolated perfused rat hindlimbs. Clin Exp Pharmacol Physiol. 1990;17:335-350.
14. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazepril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation. 1992;86: 100-110.
15. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, Clowes AW, Harker LA. Effects of angiotensin-converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension. 1991;18(suppl II):II-70-II-76.
16. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245: 186-188.
17. Roux SP, Clozel JP, Kuhn H. Cilazapril inhibits wall thickening of vein bypass graft in the rat. Hypertension. 1991;18(suppl II):II-43-II-46.
18. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
19. Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, Husain A. Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 1991;266:17173-17179.
20. Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem. 1991;266:19192-19197.
21. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens. 1994;12:S17-S22.
22. Urata H, Boehm KD, Philip A, Kinosita A, Gabrovsek J, Bumpus FM, Hussain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:S1269-S1281.
23. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, Roden RL, Peacock SJ, Groves BM, Raynolds MV, et al. Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest. 1995;96: 1490-1498.
24. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
25. DiSalvo J, Peterson A, Monterfusco C, Menta M. Intrarenal conversion of angiotensin I to angiotensin II in the dog. Circ Res. 1971;29:398-406.
26. Murakami M, Matsuda H, Kubota E, Wakino S, Honda M, Hayashi K, Saruta T. Role of angiotensin II generated by angiotensin converting enzyme-independent pathways in canine kidney. Kidney Int. 1997;52: S132-S135.
27. Hoit BD, Shao Y, Kinoshita A, Gabel M, Husain A, Walsh RA. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest. 1995;95:1519-1527.
28. Miura S-I, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, Tanaka H, Shindo M, Arakawa K. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens. 1994;12: 1177-1181.
29. Wood JM. Alternative ways to inhibit the renin-angiotensin system: general overview. In: MacGregor GA, Sever PS, eds. Current Advances in ACE Inhibition, Vol 2. London, UK: Churchill Livingstone; 1991:110-117.
30. Timmermans PBMWM, Carini DJ, Chiu AT, Duncia JV, Hervlin WF, Price WA Jr, Smith RD, Wells GJ, Wong PC, Wexler RR, Johnson AL. Nonpeptide Ang II receptor antagonists: a novel approach to inhibit the renin-angiotensin system. In: MacGregor GA, Sever PS, eds. Current Advances in ACE Inhibition, Vol 2. London, UK: Churchill Livingstone; 1991:118-124.
31. Cordero PL, Fisher NDL, Moore TJ, Gleason R, Williams GH, Hollenberg NK. Renal and endocrine response to a renin inhibitor, enalkiren, in normal renin humans. Hypertension. 1991;17:510-516.
32. Fisher NDL, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension. 1994;23:44-51.
33. Fisher NDL, Hollenberg NK. Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther. 1995;57:342-348.
34. Siragy HM, Lamb NE, Rose CE Jr, Peach MJ, Carey RM. Intrarenal renin inhibition increases renal function by an angiotensin II-dependent mechanism. Am J Physiol. 1988;363:F749-F754.
35. Price D, Porter L, DeOliveira J, Fisher N, Gordon M, Laffel L, Williams G, Hollenberg N. The paradox of the low-renin state: hormonal and renal responses to an Ang II antagonist, Irbesartan, in diabetic nephropathy. J Am Soc Nephrol. 1996;7:163. Abstract.
36. Price DA, De'Oliveira JM, Fisher NDL, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension. 1997;30:240-246.